Literature DB >> 23113741

Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.

Channakeshava S Umeshappa1, Roopa H Nanjundappa, Yufeng Xie, Andrew Freywald, Qingyong Xu, Jim Xiang.   

Abstract

Increased CD8(+) T-cell precursor frequency (PF) precludes the requirement of CD4(+) helper T (Th) cells for primary CD8(+) cytotoxic T-lymphocyte (CTL) responses. However, the key questions of whether unhelped CTLs generated at higher PF are functional effectors, and whether unhelped CTLs can differentiate into functional memory cells at higher PF are unclear. In this study, ovalbumin (OVA) -pulsed dendritic cells (DC(OVA)) derived from C57BL/6, CD40 knockout (CD40(-/-)) or CD40 ligand knockout (CD40L(-/-)) mice were used to immunize C57BL/6, Ia(b-/-), CD40(-/-) or CD40L(-/-) mice, whose PF was previously increased with transfer of 1 × 10(6) CD8(+) T cells derived from OVA-specific T-cell receptor (TCR) transgenic OTI, OTI(CD40(-/-)) or OTI(CD40L(-/-)) mice. All the immunized mice were then assessed for effector and memory CTL responses. Following DC immunization, relatively comparable CTL priming occurred without CD4(+) T-cell help and Th-provided CD40/CD40L signalling. In addition, the unhelped CTLs were functional effectors capable of inducing therapeutic immunity against established OVA-expressing tumours. In contrast, the functional memory development of CTLs was severely impaired in the absence of CD4(+) T-cell help and CD40/CD40L signalling. Finally, unhelped memory CTLs failed to protect mice against lethal tumour challenge. Taken together, these results demonstrate that CD4(+) T-cell help at higher PF, is not required for effector CTL priming, but is required for functional memory CTL development against cancer. Our data may impact the development of novel preventive and therapeutic approaches in cancer patients with compromised CD4(+) T-cell functions.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23113741      PMCID: PMC3719941          DOI: 10.1111/imm.12033

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.

Authors:  Pouneh Dokouhaki; Mei Han; Betty Joe; Ming Li; Michael R Johnston; Ming-Sound Tsao; Li Zhang
Journal:  Cancer Lett       Date:  2010-05-26       Impact factor: 8.679

2.  Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.

Authors:  Yuji Sato; Hiroki Shomura; Yoshiaki Maeda; Takashi Mine; Yoshie Une; Yoshinobu Akasaka; Masao Kondo; Shusaku Takahashi; Toshiki Shinohara; Kazuko Katagiri; Mika Sato; Shiori Okada; Kanae Matsui; Akira Yamada; Hideaki Yamana; Kyogo Itoh; Satoru Todo
Journal:  Cancer Sci       Date:  2003-09       Impact factor: 6.716

3.  A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory.

Authors:  Christine Bourgeois; Benedita Rocha; Corinne Tanchot
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

4.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

Authors:  J P Ridge; F Di Rosa; P Matzinger
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

5.  Interleukin 2 production by alloantigen-stimulated CD4+ and CD8+ human T cell subsets: frequency of HLA class I or class II-reactive precursor cells and clonal specificity of activated T cells.

Authors:  J Jooss; T H Eiermann; H Wagner; D Kabelitz
Journal:  Immunobiology       Date:  1989-10       Impact factor: 3.144

6.  Specific autologous anti-melanoma T cell response in vitro using monocyte-derived dendritic cells.

Authors:  A Soruri; A Fayyazi; R Gieseler; T Schlott; T M Rünger; C Neumann; J H Peters
Journal:  Immunobiology       Date:  1998-03       Impact factor: 3.144

7.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

8.  Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.

Authors:  R A Maas; M J Becker; I S Weimar; J C De Nooy; H F Dullens; W D Den Otter
Journal:  Immunobiology       Date:  1993-07       Impact factor: 3.144

9.  Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4.

Authors:  A Rahemtulla; W P Fung-Leung; M W Schilham; T M Kündig; S R Sambhara; A Narendran; A Arabian; A Wakeham; C J Paige; R M Zinkernagel
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

10.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

Authors:  Joseph C Sun; Matthew A Williams; Michael J Bevan
Journal:  Nat Immunol       Date:  2004-08-08       Impact factor: 25.606

View more
  4 in total

1.  Post-shock mesenteric lymph drainage ameliorates cellular immune function in rats following hemorrhagic shock.

Authors:  Hua Liu; Zi-Gang Zhao; Li-Qiang Xing; Li-Min Zhang; Chun-Yu Niu
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 2.  Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Milad Ahmadi Najafabadi; Fatemeh Yousefi; Seyed Mohamad Javad Mirarefin; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 3.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

4.  An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression.

Authors:  Liu Wang; Guangzhe Li; Lei Cao; Yi Dong; Yang Wang; Shisheng Wang; Yueqing Li; Xiuhan Guo; Yi Zhang; Fangfang Sun; Xuemei Du; Jiangan Su; Qing Li; Xiaojun Peng; Kun Shao; Weijie Zhao
Journal:  Sci Adv       Date:  2021-10-20       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.